Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Acquired Hemophilia Treatment Market Forecast: Value Set To Climb From $13.39 Billion To $15.91 Billion
The acquired hemophilia treatment market size has demonstrated consistent expansion in recent years. This market is expected to increase from $12.83 billion in 2025 to $13.39 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.4%. The growth observed in prior periods stemmed from several factors, including the limited access to specialized hemophilia therapies, an increase in the prevalence of acquired hemophilia cases, a reliance on hospital-centric care, enhanced awareness regarding bleeding disorders, and the adoption of on-demand treatment protocols.
The market for acquired hemophilia treatment is projected to experience consistent expansion over the upcoming years. Its valuation is anticipated to reach $15.91 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.4%. This projected growth during the forecast timeframe is attributable to several factors, including breakthroughs in gene therapy technology, wider acceptance of prophylaxis treatment, the rise of personalized medicine approaches in hematology, escalating investments in hemophilia research, and improved availability of sophisticated treatment choices in developing areas. Key trends identified for the forecast period encompass a greater uptake of clotting factor replacement therapies, increased application of gene therapy for preventing hemophilia, the broadening of personalized treatment strategies for acquired hemophilia, enhanced awareness and initiatives for early diagnosis, and a concentrated effort on minimizing bleeding incidents and eliminating inhibitors.
Get A Free Sample Report With In-Depth Market Insights:
Acquired Hemophilia Treatment Market Expansion Drivers: What’s Shaping Future Growth?
An increasing number of active clinical trials is projected to fuel the future growth of the acquired hemophilia treatment market. These research studies involve human participants to assess the safety and effectiveness of novel medical treatments, interventions, or diagnostic procedures. Specifically, clinical trials evaluate the safety and efficacy of new treatments for acquired hemophilia, thereby advancing research to enhance patient outcomes and develop effective therapeutic interventions. For instance, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based trade association, noted that the count of pharmaceutical industry trials launched in the UK grew for the second consecutive year, climbing from 411 in 2022 to 426 in 2023. Consequently, a growing number of ongoing clinical trials is driving the expansion of the acquired hemophilia treatment market.
Acquired Hemophilia Treatment Market Segment Analysis And Revenue Potential
The acquired hemophilia treatment market covered in this report is segmented –
1) By Treatment Approach: Bleeding Control Therapy (On-Demand Treatment), Inhibitor Eradication Therapy (Immunosuppressive Treatment)
2) By Route of Administration: Intravenous, Subcutaneous
3) By End User: Hospitals, Specialty Hematology Clinics, Other End Users
Subsegments:
1) By Bleeding Control Therapy (On-Demand Treatment): Bypassing Agents, Recombinant Activated Factor VII (rFVIIa), Activated Prothrombin Complex Concentrates (aPCC), Recombinant Porcine Factor VIII, Desmopressin
2) By Inhibitor Eradication Therapy (Immunosuppressive Treatment): Corticosteroid Monotherapy, Corticosteroids + Cytotoxic Agents (e.g., Cyclophosphamide), Rituximab-Based Immunotherapy, Combination Immunosuppressive Regimens
Acquired Hemophilia Treatment Market Strategic Trends: What Defines The Next Growth Phase?
Major companies in the acquired hemophilia treatment market are prioritizing the development of drugs with advanced features and securing their authorization to maintain their competitive position. Approvals for drugs intended for routine prophylaxis are on the rise, primarily driven by the demand for more effective and safer options. For instance, in June 2023, Chugai Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, disclosed the final analysis data from its Japanese Phase III clinical trial (AGEHA Study) involving Hemlibra (emicizumab) for acquired hemophilia A at the 31st ISTH Annual Congress. The trial enrolled patients receiving immunosuppressive therapy as well as those for whom such therapy was not suitable. Hemlibra exhibited sustained effectiveness in controlling bleeding episodes, thus supporting its wider use in individuals with acquired hemophilia A who require timely and efficient treatment.
Acquired Hemophilia Treatment Market Key Players Shaping Industry Direction
Major companies operating in the acquired hemophilia treatment market are Roche Holding AG, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bayer AG, CSL Limited, Grifols SA, Octapharma AG, Kedrion Biopharma Inc., Sanofi SA, Sobi Inc., Chugai Pharmaceutical Co. Ltd., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Medexus Pharmaceuticals Inc., Ferring Pharmaceuticals BV, Hema Biologics LLC, Bio Products Laboratory Ltd., LFB SA
View The Full Acquired Hemophilia Treatment Market Report:
Acquired Hemophilia Treatment Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the acquired hemophilia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.